Very Early Molecular Responses During The First Two Months Of Therapy Are Highly Predicitive Of Deep Molecular Responses In Newly-Diagnosed Chronic Myeloid Leukemia In Chronic Phase(CML-CP) Patients Treated Upfront With Nilotinib
Fecha de publicación
2013Título de revista
Blood
Tipo de contenido
Publicación de congreso